<p>Ginkgo Bioworks Holdings（紐約證券交易所代碼：DNA）正在準備於 2026 年 2 月 26 日發佈其季度財報。在公告之前，投資者應注意以下幾點。</p>
<p>分析師預計 Ginkgo Bioworks Holdings 的 <strong>每股收益</strong>（EPS）為-$1.39。</p>
<p>Ginkgo Bioworks Holdings 的多頭希望聽到公司不僅超出該預期，還能提供積極的指引或下個季度的增長預測。</p>
<p>新投資者應注意，影響股票價格的往往不是盈利超預期或未達預期，而是指引（或預測）。</p>
<h3>過去的盈利表現</h3>
<p>上個季度，公司每股收益低於預期$0.21，導致次日股價下跌 20.8%。</p>
<p>以下是 Ginkgo Bioworks Holdings 的過去表現及其導致的價格變化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png"/></p>
<h3>Ginkgo Bioworks Holdings 股份表現</h3>
<p>截至 2 月 24 日，Ginkgo Bioworks Holdings 的股價為$8.86。在過去 52 周內，股價上漲了 7.99%。考慮到這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
<h3>關於 Ginkgo Bioworks Holdings</h3>
<p>Ginkgo Bioworks Holdings Inc 是細胞編程的平台，提供靈活的端到端服務，解決來自食品和農業、製藥到工業和特種化學品等多個市場的組織面臨的挑戰。公司將其運營重組為兩個運營和報告部門：細胞工程：為各行業客户提供生物研發服務；生物安全：為政府和商業客户提供服務，以識別、監測、預防、減輕並最終保護人類免受生物威脅。收入的最大部分來自細胞工程部門。</p>
<h3>深入瞭解 Ginkgo Bioworks Holdings 的財務狀況</h3>
<p><strong>市值視角：</strong> 公司的市值低於行業平均水平，表明其相較於同行規模較小。這種定位可能受到感知的增長潛力或運營規模等因素的影響。</p>
<p>** 收入挑戰：**Ginkgo Bioworks Holdings 在過去 3 個月的收入增長面臨困難。截至 2025 年 9 月 30 日，公司經歷了約 <strong>-56.39%</strong> 的下降。這表明其收入出現了下降。與競爭對手相比，公司面臨的增長率低於醫療保健行業的平均水平。</p>
<p>** 淨利潤率：**Ginkgo Bioworks Holdings 的淨利潤率令人印象深刻，超過行業平均水平。淨利潤率為 <strong>-207.93%</strong>，表明公司在盈利能力和成本管理方面表現強勁。</p>
<p>** 股本回報率（ROE）：**Ginkgo Bioworks Holdings 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-13.77%</strong>，公司可能在實現最佳財務回報方面遇到困難。</p>
<p><strong>資產回報率（ROA）：</strong> 公司的 ROA 低於行業基準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>-6.67%</strong>，公司可能需要解決從資產中產生滿意回報的挑戰。</p>
<p>** 債務管理：**Ginkgo Bioworks Holdings 的債務與股本比率低於行業平均水平，為 <strong>0.76</strong>，反映出對債務融資的依賴較低，財務策略更為保守。</p>
<p>要跟蹤 Ginkgo Bioworks Holdings 的所有財報發佈，請訪問我們網站上的財報日曆。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

紐交所高增長板生物技術指數 ETF - First Trust

DNABW

2 倍做多納斯達克生物技術 ETF - ProShares

IBBQ

生物科技 ETF - VanEck Vectors

<p>Ginkgo Bioworks Holdings（紐約證券交易所代碼：DNA）將於 2026 年 2 月 26 日公佈季度財報，分析師預測每股收益（EPS）為-1.39 美元。投資者對積極的指引充滿期待，因為之前的每股收益未達預期導致股價下跌 20.8%。目前股價為 8.86 美元，過去一年上漲了 7.99%。公司面臨收入挑戰，增長率下降了 56.39%，但保持了強勁的淨利潤率，達到了-207.93%。Ginkgo 專注於細胞編程和生物安全，債務與股本比率為 0.76，屬於保守水平</p>

<p>Ginkgo Bioworks Holdings (NYSE: DNA) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings（紐約證券交易所代碼：DNA）正在準備於 2026 年 2 月 26 日發佈其季度財報。在公告之前，投資者應注意以下幾點。</p>
</div><p>Analysts expect Ginkgo Bioworks Holdings to report an <strong>earnings per share</strong> (EPS) of $-1.39.</p>
<div class="lb-trans"><p>分析師預計 Ginkgo Bioworks Holdings 的 <strong>每股收益</strong>（EPS）為-$1.39。</p>
</div><p>Ginkgo Bioworks Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings 的多頭希望聽到公司不僅超出該預期，還能提供積極的指引或下個季度的增長預測。</p>
</div><p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<div class="lb-trans"><p>新投資者應注意，影響股票價格的往往不是盈利超預期或未達預期，而是指引（或預測）。</p>
</div><h3>Past Earnings Performance</h3>
<div class="lb-trans"><h3>過去的盈利表現</h3>
</div><p>Last quarter the company missed EPS by $0.21, which was followed by a 20.8% drop in the share price the next day.</p>
<div class="lb-trans"><p>上個季度，公司每股收益低於預期$0.21，導致次日股價下跌 20.8%。</p>
</div><p>Here's a look at Ginkgo Bioworks Holdings's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Ginkgo Bioworks Holdings 的過去表現及其導致的價格變化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1772042555_0.png"/></p>
<h3>Performance of Ginkgo Bioworks Holdings Shares</h3>
<div class="lb-trans"><h3>Ginkgo Bioworks Holdings 股份表現</h3>
</div><p>Shares of Ginkgo Bioworks Holdings were trading at $8.86 as of February 24. Over the last 52-week period, shares are up 7.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 24 日，Ginkgo Bioworks Holdings 的股價為$8.86。在過去 52 周內，股價上漲了 7.99%。考慮到這些回報通常是積極的，長期股東在此次財報發佈前可能持樂觀態度。</p>
</div><h3>About Ginkgo Bioworks Holdings</h3>
<div class="lb-trans"><h3>關於 Ginkgo Bioworks Holdings</h3>
</div><p>Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&amp;D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings Inc 是細胞編程的平台，提供靈活的端到端服務，解決來自食品和農業、製藥到工業和特種化學品等多個市場的組織面臨的挑戰。公司將其運營重組為兩個運營和報告部門：細胞工程：為各行業客户提供生物研發服務；生物安全：為政府和商業客户提供服務，以識別、監測、預防、減輕並最終保護人類免受生物威脅。收入的最大部分來自細胞工程部門。</p>
</div><h3>A Deep Dive into Ginkgo Bioworks Holdings's Financials</h3>
<div class="lb-trans"><h3>深入瞭解 Ginkgo Bioworks Holdings 的財務狀況</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值視角：</strong> 公司的市值低於行業平均水平，表明其相較於同行規模較小。這種定位可能受到感知的增長潛力或運營規模等因素的影響。</p>
</div><p><strong>Revenue Challenges:</strong> Ginkgo Bioworks Holdings's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately <strong>-56.39%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p>** 收入挑戰：**Ginkgo Bioworks Holdings 在過去 3 個月的收入增長面臨困難。截至 2025 年 9 月 30 日，公司經歷了約 <strong>-56.39%</strong> 的下降。這表明其收入出現了下降。與競爭對手相比，公司面臨的增長率低於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> Ginkgo Bioworks Holdings's net margin is impressive, surpassing industry averages. With a net margin of <strong>-207.93%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<div class="lb-trans"><p>** 淨利潤率：**Ginkgo Bioworks Holdings 的淨利潤率令人印象深刻，超過行業平均水平。淨利潤率為 <strong>-207.93%</strong>，表明公司在盈利能力和成本管理方面表現強勁。</p>
</div><p><strong>Return on Equity (ROE):</strong> Ginkgo Bioworks Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-13.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p>** 股本回報率（ROE）：**Ginkgo Bioworks Holdings 的 ROE 低於行業平均水平，表明在有效利用股本方面可能面臨挑戰。ROE 為 <strong>-13.77%</strong>，公司可能在實現最佳財務回報方面遇到困難。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-6.67%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 公司的 ROA 低於行業基準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>-6.67%</strong>，公司可能需要解決從資產中產生滿意回報的挑戰。</p>
</div><p><strong>Debt Management:</strong> Ginkgo Bioworks Holdings's debt-to-equity ratio is below the industry average at <strong>0.76</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p>** 債務管理：**Ginkgo Bioworks Holdings 的債務與股本比率低於行業平均水平，為 <strong>0.76</strong>，反映出對債務融資的依賴較低，財務策略更為保守。</p>
</div><p>To track all earnings releases for Ginkgo Bioworks Holdings visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟蹤 Ginkgo Bioworks Holdings 的所有財報發佈，請訪問我們網站上的財報日曆。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

關於 Ginkgo Bioworks Holdings 即將發佈的財報的深入分析